{"bundle_type":"pith_open_graph_bundle","bundle_version":"1.0","pith_number":"pith:2019:V4Y5M6IUKCJIKGSYKHRGVDKI7W","short_pith_number":"pith:V4Y5M6IU","canonical_record":{"source":{"id":"1901.08365","kind":"arxiv","version":1},"metadata":{"license":"http://arxiv.org/licenses/nonexclusive-distrib/1.0/","primary_cat":"stat.ME","submitted_at":"2019-01-24T11:50:01Z","cross_cats_sorted":[],"title_canon_sha256":"da0ce9eff2db106582cc78393045c0c05117a8208be326de0987d77c2fce71fb","abstract_canon_sha256":"65efbfe25dd8d3c159bbdcb1c74b8cfeec228bc5909357c173ba551a2c487e7c"},"schema_version":"1.0"},"canonical_sha256":"af31d679145092851a5851e26a8d48fd9a60bb45ff1b560816db5dc0f1212182","source":{"kind":"arxiv","id":"1901.08365","version":1},"source_aliases":[{"alias_kind":"arxiv","alias_value":"1901.08365","created_at":"2026-05-17T23:55:35Z"},{"alias_kind":"arxiv_version","alias_value":"1901.08365v1","created_at":"2026-05-17T23:55:35Z"},{"alias_kind":"doi","alias_value":"10.48550/arxiv.1901.08365","created_at":"2026-05-17T23:55:35Z"},{"alias_kind":"pith_short_12","alias_value":"V4Y5M6IUKCJI","created_at":"2026-05-18T12:33:30Z"},{"alias_kind":"pith_short_16","alias_value":"V4Y5M6IUKCJIKGSY","created_at":"2026-05-18T12:33:30Z"},{"alias_kind":"pith_short_8","alias_value":"V4Y5M6IU","created_at":"2026-05-18T12:33:30Z"}],"events":[{"event_type":"record_created","subject_pith_number":"pith:2019:V4Y5M6IUKCJIKGSYKHRGVDKI7W","target":"record","payload":{"canonical_record":{"source":{"id":"1901.08365","kind":"arxiv","version":1},"metadata":{"license":"http://arxiv.org/licenses/nonexclusive-distrib/1.0/","primary_cat":"stat.ME","submitted_at":"2019-01-24T11:50:01Z","cross_cats_sorted":[],"title_canon_sha256":"da0ce9eff2db106582cc78393045c0c05117a8208be326de0987d77c2fce71fb","abstract_canon_sha256":"65efbfe25dd8d3c159bbdcb1c74b8cfeec228bc5909357c173ba551a2c487e7c"},"schema_version":"1.0"},"canonical_sha256":"af31d679145092851a5851e26a8d48fd9a60bb45ff1b560816db5dc0f1212182","receipt":{"kind":"pith_receipt","key_id":"pith-v1-2026-05","algorithm":"ed25519","signed_at":"2026-05-17T23:55:35.674642Z","signature_b64":"0v9lWdJtkEd+/uakW4McB0zBDpj5F1PJF0ilkAckYl9RF060YXD2OR9HW1Q3KmrItEBeploAeZu6VJLenwXJAQ==","signed_message":"canonical_sha256_bytes","builder_version":"pith-number-builder-2026-05-17-v1","receipt_version":"0.3","canonical_sha256":"af31d679145092851a5851e26a8d48fd9a60bb45ff1b560816db5dc0f1212182","last_reissued_at":"2026-05-17T23:55:35.674177Z","signature_status":"signed_v1","first_computed_at":"2026-05-17T23:55:35.674177Z","public_key_fingerprint":"8d4b5ee74e4693bcd1df2446408b0d54"},"source_kind":"arxiv","source_id":"1901.08365","source_version":1,"attestation_state":"computed"},"signer":{"signer_id":"pith.science","signer_type":"pith_registry","key_id":"pith-v1-2026-05","public_key_fingerprint":"8d4b5ee74e4693bcd1df2446408b0d54"},"created_at":"2026-05-17T23:55:35Z","supersedes":[],"prev_event":null,"signature":{"signature_status":"signed_v1","algorithm":"ed25519","key_id":"pith-v1-2026-05","public_key_fingerprint":"8d4b5ee74e4693bcd1df2446408b0d54","signature_b64":"YuAC0ha1jD25IDS5gyBleEidfWMph8SQDBFNLo1+UEfBUEDhQfVrUmpg5ZGD3aXg70M3/lkcys3eLr3UnzgxBg==","signed_message":"open_graph_event_sha256_bytes","signed_at":"2026-06-23T01:18:12.097196Z"},"content_sha256":"8bc501beeb48a837140935a2116b3422108570c62056f106d48c33a5c099aadd","schema_version":"1.0","event_id":"sha256:8bc501beeb48a837140935a2116b3422108570c62056f106d48c33a5c099aadd"},{"event_type":"graph_snapshot","subject_pith_number":"pith:2019:V4Y5M6IUKCJIKGSYKHRGVDKI7W","target":"graph","payload":{"graph_snapshot":{"paper":{"title":"Seamless phase II/III clinical trials using early outcomes for treatment or subgroup selection: Methods and aspects of their implementation","license":"http://arxiv.org/licenses/nonexclusive-distrib/1.0/","headline":"","cross_cats":[],"primary_cat":"stat.ME","authors_text":"Nicholas Parsons, Nigel Stallard, Tim Friede","submitted_at":"2019-01-24T11:50:01Z","abstract_excerpt":"Adaptive seamless designs combine confirmatory testing, a domain of phase III trials, with features such as treatment or subgroup selection, typically associated with phase II trials. They promise to increase the efficiency of development programmes of new drugs, e.g. in terms of sample size and / or development time. It is well acknowledged that adaptive designs are more involved from a logistical perspective and require more upfront planning, often in form of extensive simulation studies, than conventional approaches. Here we present a framework for adaptive treatment and subgroup selection "},"claims":{"count":0,"items":[],"snapshot_sha256":"258153158e38e3291e3d48162225fcdb2d5a3ed65a07baac614ab91432fd4f57"},"source":{"id":"1901.08365","kind":"arxiv","version":1},"verdict":{"id":null,"model_set":{},"created_at":null,"strongest_claim":"","one_line_summary":"","pipeline_version":null,"weakest_assumption":"","pith_extraction_headline":""},"references":{"count":0,"sample":[],"resolved_work":0,"snapshot_sha256":"258153158e38e3291e3d48162225fcdb2d5a3ed65a07baac614ab91432fd4f57","internal_anchors":0},"formal_canon":{"evidence_count":0,"snapshot_sha256":"258153158e38e3291e3d48162225fcdb2d5a3ed65a07baac614ab91432fd4f57"},"author_claims":{"count":0,"strong_count":0,"snapshot_sha256":"258153158e38e3291e3d48162225fcdb2d5a3ed65a07baac614ab91432fd4f57"},"builder_version":"pith-number-builder-2026-05-17-v1"},"verdict_id":null},"signer":{"signer_id":"pith.science","signer_type":"pith_registry","key_id":"pith-v1-2026-05","public_key_fingerprint":"8d4b5ee74e4693bcd1df2446408b0d54"},"created_at":"2026-05-17T23:55:35Z","supersedes":[],"prev_event":null,"signature":{"signature_status":"signed_v1","algorithm":"ed25519","key_id":"pith-v1-2026-05","public_key_fingerprint":"8d4b5ee74e4693bcd1df2446408b0d54","signature_b64":"rBLOlWOA0DPlkvu3CH1tS26J1z1ODYvZFrpGSvIcq0trGIV9t0fzRj/dB1DSofdT4V6s28oqDnvlqAdn60IkAg==","signed_message":"open_graph_event_sha256_bytes","signed_at":"2026-06-23T01:18:12.097555Z"},"content_sha256":"bcc6bcfd1d292698031f97f72430a2d49bb1e37103071f2695415158055f3147","schema_version":"1.0","event_id":"sha256:bcc6bcfd1d292698031f97f72430a2d49bb1e37103071f2695415158055f3147"}],"timestamp_proofs":[],"mirror_hints":[{"mirror_type":"https","name":"Pith Resolver","base_url":"https://pith.science","bundle_url":"https://pith.science/pith/V4Y5M6IUKCJIKGSYKHRGVDKI7W/bundle.json","state_url":"https://pith.science/pith/V4Y5M6IUKCJIKGSYKHRGVDKI7W/state.json","well_known_bundle_url":"https://pith.science/.well-known/pith/V4Y5M6IUKCJIKGSYKHRGVDKI7W/bundle.json","status":"primary"}],"public_keys":[{"key_id":"pith-v1-2026-05","algorithm":"ed25519","format":"raw","public_key_b64":"stVStoiQhXFxp4s2pdzPNoqVNBMojDU/fJ2db5S3CbM=","public_key_hex":"b2d552b68890857171a78b36a5dccf368a953413288c353f7c9d9d6f94b709b3","fingerprint_sha256_b32_first128bits":"RVFV5Z2OI2J3ZUO7ERDEBCYNKS","fingerprint_sha256_hex":"8d4b5ee74e4693bcd1df2446408b0d54","rotates_at":null,"url":"https://pith.science/pith-signing-key.json","notes":"Pith uses this Ed25519 key to sign canonical record SHA-256 digests. Verify with: ed25519_verify(public_key, message=canonical_sha256_bytes, signature=base64decode(signature_b64))."}],"merge_version":"pith-open-graph-merge-v1","built_at":"2026-06-23T01:18:12Z","links":{"resolver":"https://pith.science/pith/V4Y5M6IUKCJIKGSYKHRGVDKI7W","bundle":"https://pith.science/pith/V4Y5M6IUKCJIKGSYKHRGVDKI7W/bundle.json","state":"https://pith.science/pith/V4Y5M6IUKCJIKGSYKHRGVDKI7W/state.json","well_known_bundle":"https://pith.science/.well-known/pith/V4Y5M6IUKCJIKGSYKHRGVDKI7W/bundle.json"},"state":{"state_type":"pith_open_graph_state","state_version":"1.0","pith_number":"pith:2019:V4Y5M6IUKCJIKGSYKHRGVDKI7W","merge_version":"pith-open-graph-merge-v1","event_count":2,"valid_event_count":2,"invalid_event_count":0,"equivocation_count":0,"current":{"canonical_record":{"metadata":{"abstract_canon_sha256":"65efbfe25dd8d3c159bbdcb1c74b8cfeec228bc5909357c173ba551a2c487e7c","cross_cats_sorted":[],"license":"http://arxiv.org/licenses/nonexclusive-distrib/1.0/","primary_cat":"stat.ME","submitted_at":"2019-01-24T11:50:01Z","title_canon_sha256":"da0ce9eff2db106582cc78393045c0c05117a8208be326de0987d77c2fce71fb"},"schema_version":"1.0","source":{"id":"1901.08365","kind":"arxiv","version":1}},"source_aliases":[{"alias_kind":"arxiv","alias_value":"1901.08365","created_at":"2026-05-17T23:55:35Z"},{"alias_kind":"arxiv_version","alias_value":"1901.08365v1","created_at":"2026-05-17T23:55:35Z"},{"alias_kind":"doi","alias_value":"10.48550/arxiv.1901.08365","created_at":"2026-05-17T23:55:35Z"},{"alias_kind":"pith_short_12","alias_value":"V4Y5M6IUKCJI","created_at":"2026-05-18T12:33:30Z"},{"alias_kind":"pith_short_16","alias_value":"V4Y5M6IUKCJIKGSY","created_at":"2026-05-18T12:33:30Z"},{"alias_kind":"pith_short_8","alias_value":"V4Y5M6IU","created_at":"2026-05-18T12:33:30Z"}],"graph_snapshots":[{"event_id":"sha256:bcc6bcfd1d292698031f97f72430a2d49bb1e37103071f2695415158055f3147","target":"graph","created_at":"2026-05-17T23:55:35Z","signer":{"key_id":"pith-v1-2026-05","public_key_fingerprint":"8d4b5ee74e4693bcd1df2446408b0d54","signer_id":"pith.science","signer_type":"pith_registry"},"payload":{"graph_snapshot":{"author_claims":{"count":0,"snapshot_sha256":"258153158e38e3291e3d48162225fcdb2d5a3ed65a07baac614ab91432fd4f57","strong_count":0},"builder_version":"pith-number-builder-2026-05-17-v1","claims":{"count":0,"items":[],"snapshot_sha256":"258153158e38e3291e3d48162225fcdb2d5a3ed65a07baac614ab91432fd4f57"},"formal_canon":{"evidence_count":0,"snapshot_sha256":"258153158e38e3291e3d48162225fcdb2d5a3ed65a07baac614ab91432fd4f57"},"paper":{"abstract_excerpt":"Adaptive seamless designs combine confirmatory testing, a domain of phase III trials, with features such as treatment or subgroup selection, typically associated with phase II trials. They promise to increase the efficiency of development programmes of new drugs, e.g. in terms of sample size and / or development time. It is well acknowledged that adaptive designs are more involved from a logistical perspective and require more upfront planning, often in form of extensive simulation studies, than conventional approaches. Here we present a framework for adaptive treatment and subgroup selection ","authors_text":"Nicholas Parsons, Nigel Stallard, Tim Friede","cross_cats":[],"headline":"","license":"http://arxiv.org/licenses/nonexclusive-distrib/1.0/","primary_cat":"stat.ME","submitted_at":"2019-01-24T11:50:01Z","title":"Seamless phase II/III clinical trials using early outcomes for treatment or subgroup selection: Methods and aspects of their implementation"},"references":{"count":0,"internal_anchors":0,"resolved_work":0,"sample":[],"snapshot_sha256":"258153158e38e3291e3d48162225fcdb2d5a3ed65a07baac614ab91432fd4f57"},"source":{"id":"1901.08365","kind":"arxiv","version":1},"verdict":{"created_at":null,"id":null,"model_set":{},"one_line_summary":"","pipeline_version":null,"pith_extraction_headline":"","strongest_claim":"","weakest_assumption":""}},"verdict_id":null}}],"author_attestations":[],"timestamp_anchors":[],"storage_attestations":[],"citation_signatures":[],"replication_records":[],"corrections":[],"mirror_hints":[],"record_created":{"event_id":"sha256:8bc501beeb48a837140935a2116b3422108570c62056f106d48c33a5c099aadd","target":"record","created_at":"2026-05-17T23:55:35Z","signer":{"key_id":"pith-v1-2026-05","public_key_fingerprint":"8d4b5ee74e4693bcd1df2446408b0d54","signer_id":"pith.science","signer_type":"pith_registry"},"payload":{"attestation_state":"computed","canonical_record":{"metadata":{"abstract_canon_sha256":"65efbfe25dd8d3c159bbdcb1c74b8cfeec228bc5909357c173ba551a2c487e7c","cross_cats_sorted":[],"license":"http://arxiv.org/licenses/nonexclusive-distrib/1.0/","primary_cat":"stat.ME","submitted_at":"2019-01-24T11:50:01Z","title_canon_sha256":"da0ce9eff2db106582cc78393045c0c05117a8208be326de0987d77c2fce71fb"},"schema_version":"1.0","source":{"id":"1901.08365","kind":"arxiv","version":1}},"canonical_sha256":"af31d679145092851a5851e26a8d48fd9a60bb45ff1b560816db5dc0f1212182","receipt":{"algorithm":"ed25519","builder_version":"pith-number-builder-2026-05-17-v1","canonical_sha256":"af31d679145092851a5851e26a8d48fd9a60bb45ff1b560816db5dc0f1212182","first_computed_at":"2026-05-17T23:55:35.674177Z","key_id":"pith-v1-2026-05","kind":"pith_receipt","last_reissued_at":"2026-05-17T23:55:35.674177Z","public_key_fingerprint":"8d4b5ee74e4693bcd1df2446408b0d54","receipt_version":"0.3","signature_b64":"0v9lWdJtkEd+/uakW4McB0zBDpj5F1PJF0ilkAckYl9RF060YXD2OR9HW1Q3KmrItEBeploAeZu6VJLenwXJAQ==","signature_status":"signed_v1","signed_at":"2026-05-17T23:55:35.674642Z","signed_message":"canonical_sha256_bytes"},"source_id":"1901.08365","source_kind":"arxiv","source_version":1}}},"equivocations":[],"invalid_events":[],"applied_event_ids":["sha256:8bc501beeb48a837140935a2116b3422108570c62056f106d48c33a5c099aadd","sha256:bcc6bcfd1d292698031f97f72430a2d49bb1e37103071f2695415158055f3147"],"state_sha256":"f50d9fa8deeb8d4a5ff27d0c99e303ae63e8d47fea24dceb01556d036a29c740"},"bundle_signature":{"signature_status":"signed_v1","algorithm":"ed25519","key_id":"pith-v1-2026-05","public_key_fingerprint":"8d4b5ee74e4693bcd1df2446408b0d54","signature_b64":"/QQ4ItBafKqGU6JiHe1ZB8Bndy4gkrz4UEGbLV9fQyBLhUw5lDrpwm7Hvy/q6SsMrxTcJ6Y+uhzKUyptVdaDBQ==","signed_message":"bundle_sha256_bytes","signed_at":"2026-06-23T01:18:12.099579Z","bundle_sha256":"4796fed627ea90e5cf287c9b35f45aa827bfdf18373a8b54d0c4dce0d2e23dc1"}}